Analysts Are Bullish on Top Healthcare Stocks: Verona Pharma Plc (VRNA), Intra-Cellular Therapies (ITCI)


There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Verona Pharma Plc (VRNA), Intra-Cellular Therapies (ITCI) and Adaptimmune Therapeutics (ADAP) with bullish sentiments.

Verona Pharma Plc (VRNA)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Verona Pharma Plc, with a price target of $56. The company’s shares opened today at $5.60, close to its 52-week low of $5.52.

According to TipRanks.com, Moussatos has currently no stars on a ranking scale of 0-5 stars, with an average return of -10.7% and a 35.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Catabasis Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Verona Pharma Plc with a $31 average price target.

See today’s analyst top recommended stocks >>

Intra-Cellular Therapies (ITCI)

In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Intra-Cellular Therapies, with a price target of $28. The company’s shares opened today at $14.09.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.6% and a 50.5% success rate. Baral covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Global Blood Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Intra-Cellular Therapies with a $28.50 average price target, a 102.3% upside from current levels. In a report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $26 price target.

Adaptimmune Therapeutics (ADAP)

In a report released today, Marc Frahm from Cowen & Co. maintained a Buy rating on Adaptimmune Therapeutics. The company’s shares opened today at $4.64, close to its 52-week low of $3.60.

According to TipRanks.com, Frahm is a 3-star analyst with an average return of 5.4% and a 60.7% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Odonate Therapeutics Llc, Magenta Therapeutics Inc, and Unum Therapeutics Inc.

The the analyst consensus on Adaptimmune Therapeutics is currently a Hold rating.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts